

REFERENCES FOR DRUG DOSAGE GUIDELINES FOR INFANTS AND OLDER CHILDREN – 7th Edition, 2018

1. Hughes HK et al (eds) *The Harriet Lane Handbook*, 21st edition. Elsevier Inc 2017.
2. Barst RJ et al. A randomized, double blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment naive children with pulmonary arterial hypertension. *Circulation* 2012; 125 (2): 324-334.
3. Hayashi AH et al Topical sucralfate: effective therapy for the management of resistant peristomal and perineal excoriation. *J Pediatr Surg* 1991 ; 26(11) : 1279-81.
4. Jovaisas B (ed) *Compendium of Pharmaceuticals and Specialties (CPS)*, 43rd Edition. Ottawa: Canadian Pharmaceutical Association; 2015.
5. Bradley JS (ed). *Nelson's Pediatric Antimicrobial Therapy--20th Edition*. American Academy of Pediatrics. 2014.
6. American Academy of Pediatrics. Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. 2015 Red Book Report of the Committee on Infectious Diseases, 30th Edition. Elk Grove Village IL: 2015.
7. Hamalainen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? *Neurology*. 1997 Apr;48(4):1100-3.
8. Schoot RA, van Dalen EC, van Ommen CH et al. Antibiotic and other lock treatments for tunneled central venous catheter-related infections in children with cancer. *Cochrane Database of Systematic Reviews* 2013 Issue 6. Art No. CD008975
9. Aronoff GR, Bennett WM (eds) *Drug Prescribing in Renal Failure*, 5th edition 2007. American College of Physicians.
10. Tighe M et al. Pharmacological treatment of children with gastro-oesophageal reflux. *Cochran Database Syst Rev*. 2014 Nov 24.
11. Metzger D. BCCH Endocrine Handout: Adrenal Steroid Therapy and Weaning. Oct2009.
<http://www.bcchildrens.ca/Services/SpecializedPediatrics/EndocrinologyDiabetesUnit/Fo rProfessionals/Handouts.htm#endocrine>
12. Choong C, Kisson N. Vasopressin in pediatric shock and cardiac arrest. *Pediatr Crit Care Med* 2008; 9:372-9.
13. Kim SY et al. Intravenous pentamidine is effective as second line *Pneumocystis pneumonia* prophylaxis in pediatric oncology patients. *Pediatr Blood Cancer* 2008; 50: 779-783.
14. Vondracek P et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. *Eur J Paediatr Neurol* 2009; 13(4): 332-6.
15. Saul JP et al. Intravenous Amiodarone for Incessant Tachyarrhythmias in Children. A Randomized, Double-Blind, Antiarrhythmic Drug Trial *Circulation*. 2005;112:3470-3477
16. Druka D et al. Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. *Journal of Cystic Fibrosis* 2008;7:457, 459
17. BC Guidelines for care of HIV positive pregnant women and interventions to reduce perinatal transmission. 2013. www.bcwomens.ca/health-professionals/professional-resources/hiv-aids-clinical-guidelines

18. Jan JE et al. Melatonin therapy of pediatric sleep disorders: recent advances, why it works, who are the candidates and how to treat. *Curr Pediatr Rev* 2007; 3: 21-224.
19. Poison Management Manual March 2015. B.C. Drug and Poison Information Centre, Vancouver; www.dpic.org
20. Glorieux FH. Osteogenesis Imperfecta. *Best Pract Res Clin Rheumatol* 2008. Mar;22(1): 85-100.
21. Li, BU, Lefevre F. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. *J. Pediatr Gastroenterol Nutr* 2008 Sep; 47(3): 379-93
22. CATMAT malaria guidelines May 2014, volume 35S1 from the Public Health Agency of Canada www.phac-aspc.gc.ca
23. Hamida FB et al. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. *Nephron* 1993; 63: 258-262.
24. Jongerius PH et al. Effect of botulinum toxin in the treatment of drooling: A controlled clinical trial. *Pediatrics* 2004; 114:620-7.
25. O'Brien L et al. A critical review of topical local anesthetic amethocaine (Ametop) for pediatric pain. *Pediatr Drugs* 2005; 7: 41-54.
26. Antiviral Medications for Pandemic (H1N1) 2009 Influenza: Frequently Asked Questions for Health Professionals. Published by Pharmaceutical Services Division of B.C. Ministry of Health Services. Sept 18 2009
27. Koletzko S et al. Evidence-Based Guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori Infection in Children. *J Pediatr Gastroenterol Nutr*, 2011, 53(2):230-43.
28. Hanly JG, Fitzgerald MX. Meconium ileus equivalent in older patients with cystic fibrosis. *Br Med J* 1983; 286: 1411.
29. Seiklay MG. Hypertension in children. An update on treatment strategies. *Current Opinion in Pediatrics* 2007; 19: 170-177.
30. Jones AP and Wallis C. Dornase alfa for cystic fibrosis. *The Cochrane Library* 2010, Issue 3.
31. Adelson PD, Bratton SL, Carney NA et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 11. Use of hyperosmolar therapy in the management of severe pediatric traumatic brain injury. *Pediatr Crit Care Med* 2003;4:S40-44
32. Personal communications with relevant Medical Department and Division Heads, BCCH
33. Hassall E. et al. Omeprazole for treatment of chronic erosive esophagitis in children: A multicenter study of efficacy, safety, tolerability and dose requirements. *J Pediatr*. 2000; 137: 800-7.
34. Dawkins TN et al. Safety of intravenous use of ketorolac in infants following cardiothoracic surgery. *Cardiol Young* 2009; 19:150-108.
35. Olivieri NF et al. Iron-chelating therapy and the treatment of thalassemia. *Blood* 1997; 89 (3): 739-761.
36. Committee on Nutrition. Aluminum Toxicity in Infants and Children. *Pediatrics* 1996; 97(3): 413-416

37. Update to PALS 2010 Part 14 Kleinman ME et al PALS 2010 AHA Guidelines for Cardiopulmonary Resuscitation and Emergency cardiovascular care *Circulation* 2010 122 (Suppl 3) S876-S908 (updated ref 2015)
38. Koczmarc C et al. Meperidine (Demerol) safety issues. *Dynamics (Journal of Canadian Assoc of Critical Care Nurses)* 2005;16(1): 8-12
39. Durkan AM et al. The use of darbepoetin in infants with chronic renal impairment. *Pediatr Nephrol* 2006; 21: 694-7.
40. Cies JJ, Giamalis JN. Treatment of cholestatic pruritus in children. *Am J Health-Syst Pharm* 2007;64:1157-62
41. Yoshikawa N, Nakanishi K et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. *Kidney Int* 2015; 87: 225-232
42. Maladi P, Koren G. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. *Pharmacogenetics* 2008; 9(9): 1267-84.
43. Strahlendorf C. Optimizing peripheral stem cell mobilization and harvest in very small children. *J Clin Apheresis* 2005; 20: 63-64.
44. Taketomo C (ed). *Pediatric Dosage Handbook*. 21th edition. Lexi Comp Inc. Cleveland; 2014.
45. Brunner HI et al. Pediatric SLE, towards a comprehensive management plan. *Nature Reviews Rheumatology* 2011. 7(4): 225-233.
46. Stockmann C, Sherwin CMT, Zobell JT et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III Fluoroquinolones. *Pediatr Pulmonol* 2013;48:2011-20.
47. Lerner G et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. *Pediatr Nephrol* 2002; 17: 933-7.
48. BCCH Algorithm for Croup in the Emergency Department March, 2012.
49. James PJ et al. The addition of ketamine to a morphine nurse-or patient-controlled analgesia infusion (PCA/NCA) increases analgesic efficacy in children with mucositis pain. *Pediatr Anesthes* 2010; 20: 805-11.
50. Rowland AG et al. Review of the efficacy of rectal paraldehyde in the management of acute and prolonged tonic-clonic convulsions. *Arch Dis Child* 2009; 94: 720-723.
51. Croup: Pharmacologic and Supportive Interventions. UpToDate. Online access May 14, 2015
52. Laer S et al. Development of a safe and effective pediatric dosing regimen based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. *J Am Coll Cardiol* 2005; 46:1322-30.
53. Vander Bijl P et al. Disinhibitory reactions to benzodiazepines: A review. *J Oral Maxillofac Surg* 1991; 49: 519-523.
54. BCCH Algorithm for Emergency Management of Asthma May 25, 2016
55. Walsh EP et al. Evaluation of a Staged Treatment Protocol for Rapid Automatic Junctional Tachycardia After Operation for Congenital Heart Disease. *J Am Coll Cardiol* 1997;29: 1046-53.
56. Cole TS, Riordan A. Vancomycin dosing in children: what is the question? *Arch Dis Child* 2013;98:994-7.

57. Greenhill L, Kollins S, Abikoff H et al. Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry* 2006; 45: 1284-93.
58. Fetus and newborn committee. Canadian Paediatric Society. Routine administration of Vitamin K to newborns. *Paediatrics and Child Health* 1997;2:429-31(reaffirmed Feb/14)
59. Clark MB et al. American Academy of Pediatrics: Clinical Report: Fluoride Use in Caries Prevention in the Primary Care Setting. *Pediatrics*, September 1, 2014, Vol 134 (3):626-633
60. Ferguson MA, Flynn JT. Rational use of antihypertensive medication in children. *Pediatr Nephrol* 2013; 29(3): 979-988.
61. Haberle et al. Suggested Guidelines for the diagnosis and management of urea cycle disorders. *Orphanet Journal of Rare Diseases* 2012;7:32
62. Lallas M et al. Wernicke encephalopathy in children and adolescents. *World J Pediatr* 2014; 10 (4): 293-8.
63. <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2000/14309a-eng.php> (Cisapride warning)
64. Sathe MN, Patel AS. Update in pediatrics: Focus on fat-soluble vitamins. *Nutrition in Clinical Practice*. 2010; 25(4): 340-346.
65. Bruns L.A. et al. Should ACE blockers be used for the chronic treatment of pediatric patients with chronic heart failure. *Pediatric Drugs* 2002; 4(12): 771-778
66. Ostman-Smith I et al. A Cohort study of childhood Hypertrophic Cardiomyopathy. *Journal of American Coll Cardiol* . 1999; 34(6) 1813-1822.
67. Manufacturer, A's literature.
68. Walsh TJ et al. Pharmacokinetics, safety and tolerability of caspofungin in children and adolescents. *Antimicrob Agents Chemother* 2005; 49(11): 4536-45.
69. Chrysostomou C et al. Dexmedetomidine use in a pediatric intensive care unit: Can we use it in infants after cardiac surgery? *Pediatr Crit Care Med* 2009; 10: 654-660.
70. Van Eyk, N et al Pediatric Vulvovaginal disorders: A diagnostic approach and review of the literature. *J Obstet Gynaecol Can* 2009; 31(9): 850-862.
71. Van Karnebeek, C. et al. Current Treatment and Management of Pyridoxine-Dependent Epilepsy. *Curr Treat Options Neurol* 2015. 17 (2): 335
72. University Medical Center, Jacksonville FL. Guidelines for phosphorous supplementation in adults. *Formulary* 1998;33:263.
73. Equi A et al. Long term azithromycin in children with cystic fibrosis : a randomised, placebo controlled crossover trial. *Lance* 2002 : 360 : 978-84.
74. Frickhofen H, et al, for the German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. *Blood* 2003;101:1236-1242.
75. Ettenger R et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. *Pediatric Transplantation* 2005 ;9 : 780-7.
76. Adefurin A, Sammons H, Jacqz-Aigrain E et al. Ciprofloxacin safety in paediatrics: a systematic review. *Arch Dis Child* 2011;96:874-80
77. Lee SH et al. Minimal effective dosage of recombinant human erythropoietin in spinal surgery. *Clin Orthop* 2003; 412: 71-6.

78. Alper A et al. Polyethylene glycol: A game-changer laxative for children. *JPGN* 2013; 57: 134-140.
79. Evans, D et al. Intravenous ketamine sedation for painful oncology procedures. *Pediatr Anesthesia* 2005; 15(2): 131-138.
80. Zimmermann AE et al. A review of omeprazole use in the treatment of acid-related disorders in children. *Clin Ther* 2001;23(5):660-79.
81. Chan HS et al. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: double-blind, crossover trial. *Pediatrics* 1987; 79(6): 946-52.
82. Fischer JH, Patel TV, Fischer PA. Fosphenytoin. Clinical Pharmacokinetics and Comparative Advantages in the Acute Treatment of Seizures. *Clin Pharmacokinet* 2003;42(1):33-58
83. Elbe, D, Bezchlibnyk-Butler K, Virani AS, Procyshyn RM (eds) 2015. *Clinical Handbook of Psychotropic Drugs for Children and Adolescents -3rd ed.* Boston MA: Hogrefe Publishing
84. Carr R et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. *J Pineal Res* 2007 ; 3 :351-59.
85. Flynn JT et al. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. *J Clin Pharmacol* 2006; 46: 905-916.
86. Schulte PFJ. Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring. *Ann Pharmacother* 2006; 40; 683-8.
87. Grond S et al. Clinical pharmacology of tramadol. *Clin Pharmacokinet* 2004; 43(13): 879-923.
88. Walker J et al. Sedation using dexmedetomidine in pediatric burn patients. *J Burn Care Res* 2006; 27: 206-10
89. Thomas J et al. Treatment of Aspergillosis : Clinical Practice Guidelines of the Infectious Diseases Society of America. *CID* 2008; 46: 327-360.
90. Monagle P et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: ACCP evidence-based clinical practice guidelines. *Chest* 2012; 141: e737S-e801S.
91. Godel JC. Canadian Paediatric Society Position Statement. Vitamin D supplementation: Recommendations for Canadian mothers and infants. *Paediatr Child Health* 2007;12(7):583-9(reaffirmed Jan 30, 2015))
92. Carr RR et al. Azithromycin for improving pulmonary function in cystic fibrosis. *Ann Pharmacother* 2004: 38: 1520-4.
93. Pappas PG et al. Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America. *CID* 2009; 48: 503-35.
94. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. *Br J Psychiatry*. 2009 Jan; 194(1):4-9.
95. Ketter TA, Wang PW, Chandler RA et al. Dermatology precautions and slower titration yield a low incidence of lamotrigine treatment emergent rash. *J Clin Psychiatry* 2005; 66: 642-5.
96. Bozkurt P. Use of tramadol in children. *Pediatric Anaesthesia* 2005; 15: 1041-7.
97. Nyhan WL. Treatment of the Acute Crisis in Maple Syrup Urine Disease. *Arch Pediatr Adolesc Med*. 1998;152:593-598

98. National Asthma Council Australia. Asthma Management Handbook Version 1.1 Melbourne March 2014
99. Zuppa AF et al. Population pharmacokinetics of ketorolac in neonates and young infants. *Am J Ther* 2009; 16(20): 143-6
100. Kimberlin DW et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. *N Engl J Med* 2015 Mar 5; 372(10): 933-43.
101. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. *Cochrane Database Syst Rev*. 2002;(2):CD002317.
102. Van harten J et al. Negligible sublingual absorption of nifedipine. *Lancet* 1987; Dec 12: 1363-4
103. Murphy JV et al. Deaths in young children receiving nitrazepam. *J Pediatr* 1987; 111 (1): 145-7.
104. Nurko S et al. PEG3350 in the treatment of childhood constipation: a multicenter, double-blinded, placebo-controlled trial. *J Pediatr* 2008; 153: 254-61.
105. Flynn JT et al. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. *Pediatr Nephrol* 2000; 15: 302-316.
106. Flynn JT et al. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. *Pediatr Nephrol* 2005; 20:631-635
107. Standing, J. F., Tibboel, D., Korpela, R. and Olkkola, K. T. (2011), Diclofenac pharmacokinetic meta-analysis and dose recommendations for surgical pain in children aged 1, Å12 years. *Pediatric Anesthesia* 2011; 21: 316, Å324.
108. Rose JB et al. Oral tramadol for the treatment of pain of 7-30 days, Å duration in children. *Anesth Analg* 2003; 96: 78-81
109. Gordillo R et al. The Nephrotic Syndrome. *Pediatr Rev* 2009; 30:94-105.
110. Batshaw ML et al. Alternative pathway therapy for urea cycle disorders: twenty years later. *J Pediatr* 2001; 138:S46-S55.
111. Gillette P, Garson A (eds) *Clinical Pediatric Arrhythmias* 2nd Ed. Philadelphia: WB Saunders: 1999.
112. Micromedex. Thomson Healthcare 2017
113. Thayu M et al. Treatment of iron deficiency anemia in pediatric inflammatory bowel disease. *Current Treatment Options in Gastroenterology* 2005; 8:411-17.
114. Nakamura A et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. *Transplant Proc* 2014; 4(2): 592-4.
115. Wuhl E et al. Strict blood pressure control and progression to end stage renal failure in children. *NEJM* 2009; 361(17); 1639-1650.
116. Jones GL et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. *BMJ* 2015; 169: 661-671
117. Young, G et al. Argatroban therapy in pediatric patients requiring non heparin anti-coagulation: An open-label safety, efficacy and pharmacokinetic study. *Pediatr Blood Cancer* 2011; 56: 1103-09.
118. Carbaglu product monograph; provided by Orphan Europe.
119. Ramamoorthy C et al. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. *Pediatr Anesthesia* 1998; 86:283-9.

120. Kane JM, Leucht S, Carpenter D, Docherty JP. Optimizing Pharmacological treatment of psychotic disorders. *Journal of Clinical Psychiatry* 2003; 64 Suppl 12; 28.
121. Burks C et al. Meperidine for the treatment of shaking chills and fever. *Arch Intern Med* 1980. 140: 483-4.
122. Madabushie R et al . Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. *J Clin Pharmacol* 2011; 51: 19-28
123. Condren et al. The Emerging Role of Hypertonic Saline in Cystic Fibrosis-Related Pulmonary Disease. *J Pediatr Pharmacol Ther* 2007; 12: 23-30.
124. Deeks ED et al. Rabbit anti-thymocyte globulin (Thymoglobuline): a review of its use in the prevention and treatment of acute allograft rejection. *Drugs* 2009; 69 (11): 1483-1512.
125. Deeg HJ et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. *Biol Blood Marrow Transplant* 2006; 12(5): 573-84.
126. Oliveira C, Nasr A, Brindle M et al. Ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: A meta-analysis. *Pediatrics* 2012;129:318,Äi329 .
127. From the Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA) 2015. Available at www.ginasthma.org
128. Malignant Hyperthermia Association of the United states: www.mhaus.org
129. Youngster I, Arcavi L, Schechmaster R et al. Medications and glucose-6-phosphate dehydrogenase deficiency. An evidence-based review. *Drug Saf* 2010;33:713-26.
130. Salvadori M, Price V. Preventing and treating children with asplenia or hyposplenia. Canadian Paediatric Society Infectious Diseases and Immunizations Committee. *Paediatr Child health* 2014; 19(5): 271-4.
131. Borowitz D et al. Concensus report on nutrition for pediatric patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 2002; 35(3):246-59.
132. Goldman RD. Codeine for acute cough in children. *Can Fam Physician* 2010; 56(12): 1293-4.
133. Health Canada Guidance Document: Non-prescription Oral Paediatric the labelling of Cough and Cold Labelling Standard. 2009
134. Kitai I, Demers A-M. Canadian Tuberculosis Standards 7th Edition. 2013. Chapter 9: Pediatric Tuberculosis
135. Managing the paediatric patient with an acute asthma exacerbation. Ortiz-Alvarez O et al; Canadian Paediatric Society, Acute Care Committee. *Paediatr Child Health* 2012; 17(5): 251-5. Reaffirmed: Feb 28, 2015.
136. SOGC Clinical Practice Guidelines. Canadian Contraception Consensus, Chapter 3: Emergency Contraception. *J Obstet Gynaecol Can* 2015; 37 (10): S20-28
137. Vaudry W et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplantation recipients. *Am J Transplant* 2009; 9: 636-43.
138. Cassidy JT, Petty RE et al (eds). *Textbook of Pediatric Rheumatology* 7th edition. Philadelphia: Elsevier Saunders: 2016.
139. Wong LS et al. Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant. *Internal Medicine Journal* 2009; 39: 379-83.

140. Monagle P et al (eds). *Andrew, A's Pediatric Thromboembolism and Stroke*. 3rd ed. 2006; BC Decker Inc. Hamilton
141. Severin PN et al. *The Pediatric Cardiology Pharmacopoeia:2013 Update*. *Pediatr Cardiol* 2013; 34: 1-29
142. Gralla RJ et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. *J Clin Oncol* 1999; 17: 2971-94. metoclopramide
143. SOGC Clinical Practice Guideline No. 313. Menstrual suppression in special circumstances. *J Obstet Gynaecol Can* 2014; 36(10): 915-24.
144. Foerster SR et al. Pediatric Heart Failure Therapy with α_1 -Adrenoceptor Antagonists. *Pediatr Drugs* 2008; 10(2): 125-134
145. Corman SL et al. Atomoxetine: The first non-stimulant for the management of ADHD. *Am J Health Sys Pharm* 2004; 16: 2391-2399.
146. Giland LS et al. Atomoxetine for the treatment of attention deficit hyperactivity disorder. *Ann Pharmacother* 2004; 38: 86-89.
147. Haymond MW et al. Mini-dose glucagon rescue for hypoglycaemia in children with type 1 diabetes. *Diabetes Care* 2001; 24(4): 643-5.
148. Di Iorgi N, Napoli F, Allegri A et al. Diabetes insipidus- Diagnosis and management. *Horm Res Paediatr* 2012;77:69-84
149. Giglia TM et al. Prevention and treatment of thrombosis in pediatric congenital heart disease. Scientific statement of AHA. *Circulation* 2013; 128: 2611-2703.
150. Canadian Paediatric Society Position Statement . Guidelines for the management of suspected and confirmed bacterial meningitis in Canadian children older than one month of age. *Paediatr Child Health* 2014; 19(3): 141-6.
151. Summar M. Current strategies for the management of neonatal urea cycle disorders. *J Pediatr* 2001; 138: S30-S39.
152. Crandall WV et al. Infusion reaction to infliximab in children and adolescents: frequency, outcome and predictive model. *Aliment Pharmacol Ther* 2003; 17: 75-84.
153. Martin-Johnston MK et al. Therapeutic amenorrhea in patients at risk for thrombocytopenia. *Obstet Gynecol Survery* 2008; 63(6): 395-402
154. Ormrod D et al. Topiramate: A review of its use in childhood epilepsy. *Pediatr Drug* 2001; 3(4): 293-319.
155. Saffel D, Marasco RA, Sengson S. Outcomes Based Therapeutic Interchange: an ACE inhibitor interchange program. *The Consultant Pharmacist [Serial online]* 1999 [cited March 2007].
156. Kimura Y et al. Treatment of chronic pain in pediatric rheumatic disease. *Nat Clin Pract Rheumatol* 2007; 3:210-218
157. Sidhu S et al. Estrogen-based therapy for acute dysfunctional uterine bleeding. *CPJ/RPC* 2006; 139(3): 60-61
158. Sidhu J, Job S, Singh S, et al, „The Pharmacokinetic and Pharmacodynamic Consequences of the Co-administration of Lamotrigine and a Combined Oral Contraceptive in Healthy Female Subjects,, Br J Clin Pharmacol, 2006, 61(2):191-9.
159. Onland W et al. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. *Arch Pediatr Adolesc Med* 2006, 160:1049-53.
160. Canadian ADHD practice guidelines Third Edition 2011 from the Canadian Attention Deficit hyperactivity Disorder Resource Alliance located at: www.caddra.ca

161. Nick JA. Non tuberculous mycobacteria in cystic fibrosis. *Seminars in Respiratory and Critical Care Medicine* 2003; 24(6): 693-702.
162. Riikonen R. Infantile spasms: therapy and outcome. *J Child Neurol* 2004;19:401-404.
163. Gore L et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. *Pediatr Blood Cancer* 2009; 52:242-7.
164. Williams DG et al. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. *Br J Anaesth* 2002; 89: 839-45.
165. Curry JJ et al. Erythromycin as a prokinetic agent in infants and children. *Aliment Pharmacol Ther* 2001; 15(5); 595-603.
166. Long R, Avendano M, Kunimoto D. *Canadian Tuberculosis Standards 7th Edition*. 2013. Chapter 8: Drug-Resistant Tuberculosis
167. Al-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant tuberculosis: pediatric guidelines. *Pediatr Infect Dis J* 2011;30:501-5.
168. Mier RJ et al. Treatment of Sialorrhea with Glycopyrrolate- A Double-blind Dose-Ranging Study. *Arch Pediatr Adolesc Med*. 2000; 154(12): 1214-1218
169. Elbe D, Carandang CG. Focus on Ziprasidone: A Review of its use in Child and Adolescent Psychiatry. *Journal of the Canadian Academy of Child and Adolescent Psychiatry* 2008; 17: 220-9
170. Public Health Agency of Canada. *Canadian Guidelines on Sexually Transmitted Infections* [Internet]. 2010 [cited 2015 May 11]. Available from: <http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-10-eng.php>
171. BCCH C. difficile order set. Approved May 13, 2014.
172. Rybak MJ et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Disease Society of America, the American Society of Health System Pharmacists and the Society of Infectious Disease Pharmacists. *CID* 2009; 49: 325-7.
173. Giachetto G et al. Ampicillin and penicillin concentration in serum and pleural fluid of hospitalized children with community-acquired pneumonia. *Pediatr Infect Dis J* 2004; 23: 625-629
174. Aaronson PMA et al. Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading dose in the ED. *Am J Emerg Med* 2010; 29: 983-988
175. Mueller EW et al. Fosphenytoin: Current place in therapy. *J Pediatr Pharmacol Ther* 2004. 9 (4):265-273
176. Emil S, Nguyen T, Sills J et al. Meconium Obstruction in Extremely Low Birth Weight Neonates: Guidelines for Diagnosis and Management. *J Pediatr Surg* 39;5:731-37
177. Reed MD et al. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. *Antimicrobial agents and Chemotherapy* 1994; 38(12): 2817-2826.
178. Cies JJ et al. Pharmacokinetics of piperacillin/tazobactam in critically ill young children. *Pediatr Infect Dis J* 2014;33:168,Ä1173
179. Shann F. *Drug Doses*. Royal Children,Äôs Hospital, Melbourne Australia. 15th Edition. 2010
180. Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. *Antimicrob Agents Chemother* 2011; 55(12): 5770-5779

181. Choi SH, Lee SY, Hwang JY, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. *Pediatr Blood Cancer* 2013;60:82-87.
182. Monitto et al. The optimal dose of prophylactic intravenous naloxone in ameliorating opioid-induced side effects in children receiving intravenous patient-controlled analgesia morphine for moderate to severe pain: a dose finding study. *Anesth Analg*. 2011. 113(4):834-42.
183. Escudero C, Carr R, Sanatani S. Overview of antiarrhythmic drug therapy for supraventricular tachycardia. *Prog Pediatr Cardiol* 2013;35:55-63.
184. Perez V, Saenz D, Madriz J et al. A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica. *Int J Infect Dis* 2011;15:e569-75
185. Greenaway M, Elbe D. Focus on Aripiprazole: A Review of its use in Child and Adolescent Psychiatry. *Journal Can Acad Child Adolesc Psychiatry* 2009; 18: 250-60.
186. Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. *J Am Med Assoc* 2009; 302: 176-573.
187. Pringsheim T, Panagiotopoulos C, Davidson J et al. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. *Pediatr Child Health* 2011; 16: 581-9.
188. Youssef NN, Mezoff AG, Carter BA et al. Medical update and potential advances in the treatment of pediatric intestinal failure. *Curr Gastroenterol Rep* 2012;14:243-52.
189. Loughheed MD, Lemiere C, Ducharme FM, et al; Canadian Thoracic Society Asthma Clinical Assembly. Canadian Thoracic Society 2012 guideline update: Diagnosis and management of asthma in preschoolers, children and adults. *Can Respir J* 2012;19(2):127-164.
190. Akhavan, A., & Bershada, S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. *American Journal of Clinical Dermatology* 2003; 4(7), 473-492.
191. Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr* 2006;43: e1-13
192. Munoz R et al (eds). *Handbook of Pediatric Cardiovascular Pharmacotherapy*. Second edition. Springer: 2014.
193. Fourth Report on Diagnosis, Evaluation and Treatment of High blood pressure in Children and Adolescents. *Pediatrics* 2004; 114(2): 555-576.
194. Del Cuavillo A et al. Use of antihistamines in pediatrics. *Investig Allergol Clin Immunol* 2007; 17 Suppl 2: 28-40.
195. Banerji A et al. Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review. *Allergy Asthma Proc*. 2007; 28(4):418, Åi426.
196. Wong-Sefdan I et al. Implementing inpatient, evidence-based, antihistamine-transfusion premedication guidelines at a single academic US hospital. *The Journal of community and supportive oncology*. 2014;12(2), 56-64.
197. Alvesco (ciclesonide inhalation aerosol). Drug Product Monograph. Nycomed Canada Inc. 2009.

198. Kelly H. Comparison of Inhaled Corticosteroids: An Update. *The Annals of Pharmacotherapy* 2009, 43:519-527
199. Khongphattbanayothin A et al. Effects of cisapride on QT interval in children. *J Pediatr* 1998;133:51-56.
200. Shulman RJ et al. An updated medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. *J Pediatr Gastroenterol Nutr* 2000; 31: 232-233.
201. World Health Organization. *Guidelines for the Treatment of Malaria*. 2nd Edition. Geneva: World Health Organization; 2010
202. Thee S, Seddon JA, Donald PR et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: Evidence for implementation of revised World Health Organization recommendations. *Antimicrob Agents Chemother* 2011;55:5560-7
203. BC Centre for Disease Control. *Tuberculosis Control Manual*. February 2012
204. Taguchi N, Nishikawa T, Inomata S et al. Hemodynamic effects of intravenous ephedrine in infants and children anesthetized with halothane and nitrous oxide. *Anesth Analg* 1996;82:568-73
205. Ly TT, Maahs DM, Rewers A et al ISPAD Clinical Practice Consensus Guidelines 2014: Assessment and management of hypoglycemia in children and adolescents with diabetes. *Pediatr Diabetes* 2014; 15 (suppl 20):180-192.
206. Shannon M, Albers G, Burkart K et al. Safety and efficacy of flumazenil in the reversal of benzodiazepine-induced conscious sedation. The flumazenil Pediatric Study Group. *J Pediatr* 1997;131:582-6.
207. Gharib H et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Growth Hormone Use in Adults and Children, 2003 Update. *Endocr Pract* 2003; 9:64-76
208. Wherrett D, Huot C, Mitchell B, et al. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Type 1 diabetes in children and adolescents. *Can J Diabetes* 2013;37:S153-62.
209. Kapoor RR, Flanagan SE, James C et al. Hyperinsulinaemic hypoglycemia. *Arch Dis Child* 2009;94:450-7
210. Brendstrup L, Hjelt K, Petersen KE et al. Nitrofurantoin versus trimethoprim prophylaxis in recurrent urinary tract infections in children. *Acta Paediatr Scand* 1990;79:1225-34.
211. Liu C, Bayer A, Cosgrove SE et al. Clinical Practice Guidelines by the Infectious Disease Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: Executive summary. *Clin Infect Dis* 2011; 52:285-92
212. Zeitlin L, Rauch F, Plotkin H et al. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, II, and IV. *Pediatrics* 2003;111:1030-6.
213. Ohata Y, Tomita Y, Nakayama Y et al. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations. *Drug Metab Pharmacokinet* 2011;26:523-31.

214. Cohen-Wolkowicz M, Poindexter B, Bidegain M. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. *Clin Infect Dis* 2012;55:1495-502.
215. Zeitler P, Fu J, Tandon N et al. ISPAD Clinical Practice Consensus Guidelines 2014: Type 2 diabetes in the child and adolescent. *Pediatric Diabetes* 2014;15(Suppl 20):26-46.
216. Panagiotopoulos C, Riddell MC, Sellers EAC. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Type 2 diabetes in children and adolescents. *Can J Diabetes* 2013;37:S163-7.
217. Ribeiro Barros E, Saraiva GL, Palomo de Oliveira T et al. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. *J Pediatr Endocr Met* 2012;25:485-91.
218. Vuorimies I, Toiviainen-Salo S, Hero M et al. Zoledronic acid treatment in children with osteogenesis imperfecta. *Horm Res Paediatr* 2011;75:346-53.
219. White NJ et al. The anesthetic effectiveness of lidocaine-adrenaline-tetracaine gel on finger laceration. *Pediatr Emerg Care* 2004; 20: 812-5
220. Priestly C et al. Application of topical local anesthetic at triage reduces treatment time for children with lacerations: A randomized controlled trial. *Ann Emerg Med* 2003; 42: 34-40.
221. Hsu DC. Topical anesthetics in children. In: UpToDate. Stack AM (ed) UpToDate. Waltham, MA. (accessed Jan 26, 2015)
222. Little C et al. The use of topical anesthesia during repair of minor lacerations in departments of emergency medicine: A literature review. *Int Emerg Nursing* 2009; 17: 99-107
223. The RIVUR trial investigators. Antimicrobial prophylaxis for children with vesicoureteral reflux. *N Engl J Med* 2014; 370:2367-76
224. Craig JC, Simpson JM, Williams GJ et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. *N Engl J Med* 2009;361:1848-59
225. Ohata Y. Intermittent oral trimethoprim/sulfamethoxazole on two non-consecutive days per week is effective as *Pneumocystis jirovecii* pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation. *Pediatr Blood Cancer* 2009;52:142-4.
226. Sung L, Manji A, Beyene J et al. Fluoroquinolones in children with fever and neutropenia. *Pediatr Infect Dis J* 2012;31:431-5
227. Bradley JS, Byinton CL, Shah SS, et al. The Management of Community Acquired Pneumonia in Infants and Children Older than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Disease Society and the Infectious Disease Society of America. *Clin Infect Dis*, 2011; 53(7): e25-76.
228. Tunkel AR, Hartman BJ, Kaplan SL, et al, Practice Guidelines for the Management of Bacterial Meningitis. *Clin Infect Dis* 2004; 39(9):1267-84
229. Le Saux N. Guidelines for the management of suspected and confirmed bacterial meningitis in Canadian children older than one month of age. Canadian Pediatric Society. *Paediatr Child Health* 2014; 19(3): 141-6.
230. Solomkin JS, Mazuski JE, Bradley JS, et al, , "Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the

Surgical Infection Society and the Infectious Diseases Society of America, *Clin Infect Dis*, 2010, 50(2):133-64.

231. Pringsheim T, Panagiotopoulos C, Davidson J et al. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. *Pediatr Child Health* 2011; 16: 581-9.
232. Ronaldson KJ, Fitzgerald PB, Taylor AJ et al. A new monitoring protocol for clozapine induced myocarditis based on an analysis of 75 cases and 94 controls. *Aust N Z J Psychiatry* 2011; 45: 458-65.
233. American Academy of Child and Adolescent Psychiatry. Practice Parameter for the Assessment and Treatment of Children and Adolescents with Obsessive-Compulsive Disorder. *J Am Acad Child Adolesc Psychiatry* 2012; 51: 98-113.
234. Warren AE, Hamilton RM, Belanger SA et al. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry. *Can J Cardiol* 2009; 25: 625-30.
235. Greil W, Bauer J, Breit J et al. Single daily dose schedule in lithium long-term treatment: effects on pharmacokinetics and on renal and cardiac functions. *Pharmacopsychiat* 1985; 18: 106-7.
236. Timmer RT, Sands JM. Lithium intoxication. *J Am Soc Nephrol*. 1999; 10: 666-74.
237. Bruni O, Alonso-Alconada D, Besag F et al. Current role of melatonin in pediatric neurology: Clinical recommendations. *Eur J Pediatr Neurol* 2015; 19: 122-33.
238. Emslie GJ, Wagner KD, Kutcher S. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2006; 45: 709-19
239. IMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For Health Professionals <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/42253a-eng.php>
240. European medicines Agency. PRAC recommends restricting use of domperidone. European Medicines Agency 2012: EMA/129231/2014
241. Health Canada. MedEffect Advisory. January 15, 2015. Domperidone , Association with Serious Abnormal Heart Rhythms and Sudden Death (Cardiac arrest) , For Health Professionals <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43423a-eng.php>
242. Escudero C et al. Medical Management of Pediatric arrhythmias. *Curr Treat Options Cardiovasc Med* 2012; 14: 455-72
243. Escudero C et al. Overview of antiarrhythmic drug therapy for supraventricular tachycardia in children. *Prog in pediatr Cardiol* 2013; 35: 55-63.
244. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines. *MMWR Morb Mortal Wkly Rep* 2010; 59 (RR 12): 26-40.
245. Petrocheilou A et al. Viral Croup: Diagnosis and a Treatment Algorithm. *Pediatric Pulmonology* 2014; 49:421-429
246. Canadian Dental Association Position on Use of Fluorides in Caries Prevention. Approved March 2003, Reaffirmed Feb 2005, Revised March 2012

247. Twycross R et al. Palliative Care Formulary- Canadian Edition. palliativedrugs.com Ltd. 2007, page 466
248. Parr J et al. The drooling reduction intervention trial: a single blind trial comparing the efficacy of glycopyrronium and hyoscine on drooling in children with neurodisability *Trials* 2014 15:60
249. BC Guidelines and Protocols Advisory Committee Iron deficiency investigation and management 2010 www2.gov.bc.ca
250. AAP 2010 Diagnosis and Prevention of iron deficiency anemia in infants and young children (0-3 yrs of age). *Pediatrics* 2010; 126(5): 2010-2576
251. Fomelloff DF et al. Iron requirements of infants and toddlers. *JPGN* 2014; 48(1): 119-129.
252. Crary SE et al. Intravenous Iron Sucrose for Children with Iron Deficiency Failing to Respond to Oral Iron Therapy. *Pediatr Blood Cancer* 2011; 56:615-619
253. Kaplinsky C et al. Magnesium Homeostasis and hypomagnesemia in children with malignancy. *Pediatr Blood Cancer* 2013;60:734-40
254. Peltola H et al. Acute osteomyelitis in children. *N Engl J Med* 2014; 370: 352-60
255. American Academy of Pediatrics, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. *Pediatrics* 2011;128(4):e1034-45.
256. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. *J Clin Oncol* 2012;30:4427-38.
257. Vanek VW, Borum P, Buchman A et al. ASPEN Position Paper: Recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. *Nutr Clin Pract*. Aug 2012; 27(4): 440-491.
258. Popvich D, McAlhany A, Adewumi AO, Barnes MM. Scurvy: Forgotten but definitely not gone. *J Pediatr Health Care*. (2009);23:405-415.
259. Nelson, A's Essentials of Pediatrics 7th edition (online version) Vitamins and Minerals Marc dante and Kleigman 2015
260. Sathe M et al. Update in pediatrics: focus on fat-soluble vitamins. *Nutrition in Clinical Practice* 2010. 25 (4): 340-346.
261. Flynn JT et al. Management of hypertension in the young: role of antihypertensive medications. *J Cardiovasc Pharmacol* 2011;58 (2): 111-120.
262. Forgie S, Zhanel G, Robinson J; Canadian Paediatric Society Infectious Diseases and Immunization Committee. Management of acute otitis media. *Paediatr Child Health* 2009;14(7):457-60.
263. Malani AN. Failure of caspofungin for treatment of *Candida glabrata* candiduria: case report and review of the literature. *Infect Dis Clin Pract* 2010;18:271.
264. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. *Clin Infect Dis* 2007;44:e46-9.
265. Cornely OA et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 2007; 356: 348-59
266. Walsh TJ et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Inf Dis* 2008; 46: 327-360.
267. Freifeld AG et al. Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. *Clin Inf Dis* 2011; 51: e56-e93.

268. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. *Antimicrob Agents Chemother* 2009;53(3):958-966.
269. Ullman AJ et al. Posaconazole or fluconazole in severe graft-versus-host disease. *N Engl J Med* 2007; 356: 335-47.
270. Allen UD; Canadian Paediatric Society. Antifungal agents for the treatment of systemic fungal infections in children. *Paediatr Child Health* 2010;15(9):603-8.
271. Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. *Cochrane Database of Systematic Reviews* 2013, Issue 12. Art. No.: CD005149. DOI: 10.1002/14651858.CD005149.pub4
272. Ortiz-Alvarez O, A Mikrogianakis; Canadian Paediatric Society, Acute Care Committee. Managing the paediatric patient with an acute asthma exacerbation. *Paediatr Child Health* 2012;17(5):251-256.
273. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. *Cochrane Database of Systematic Reviews* 2013, Issue 8. Art. No.: CD000060. DOI: 10.1002/14651858.CD000060.pub2.
274. Del Cuvillo O, et al. Use of antihistamines in pediatrics. *J Investig Allergol Clin Immuno* 2007. 17 Suppl 2: 28-40
275. Chauhan BF, Ben Salah R, Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. *Cochrane Database of Systematic Reviews* 2013, Issue 10. Art. No.: CD009585. DOI: 10.1002/14651858.CD009585.pub2.
276. Vezina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. *Cochrane Database of Systematic Reviews* 2014, Issue 7. Art. No.: CD010283. DOI: 10.1002/14651858.CD010283.pub2.
277. McDonald N, Bara A, McKean MC. Anticholinergic therapy for chronic asthma in children over two years of age. *Cochrane Database of Systematic Reviews* 2003, Issue 3. Art. No.: CD003535. DOI: 10.1002/14651858.CD003535.
278. Koninkx M et al. Management of Status Asthmaticus in Children. *Pediatric Respiratory Reviews* 2013; 14: 78-85
279. Methylprednisolone High Dose (Pulse) Therapy Protocol. Approved by BCCH PTN Dec 13, 2016.
280. Kidney International Supplements (2012) 2;292-298 Chapter 2: use of iron to treat anemia in CKD The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease
281. Jordan CP et al. Universal ECG changes in pediatric patients undergoing procainamide challenge. *PACE* 2014; 37: 1106-10.
282. Plambech MZ et al. Dexmedetomidine in the pediatrics population: a review. *Minerva Anesthesiol* 2015; 81:320-32.
283. Li BL et al. Intranasal dexmedetomidine following failed chloral hydrate sedation in children. *Anaesthesia* 2014; 69: 240-4.
284. Ibrahim M. A prospective, randomized, double blinded comparison of intranasal dexmedetomidine vs intranasal ketamine in combination with intravenous midazolam for

procedural sedation in school aged children undergoing MRI. *Anesth Essays Res* 2014; 8: 179-86.

285. Hitt JM et al. An evaluation of intranasal sufentanil and dexmedetomidine for pediatric dental sedation. *Pharmaceutics* 2014; 6: 175-84.
286. Wang SS et al. The sedative effects and the attenuation of cardiovascular and arousal responses during anesthesia induction and intubation in pediatric patients: a randomized comparison between two different doses of preoperative intranasal dexmedetomidine. *Paediatr Anaesth* 2014; 24: 275-81.
287. Rivkees SA. Pediatric Graves' disease: management in the post-propylthiouracil era. *Int J Pediatr Endocrinol.* 2014;2014(1):10. doi: 10.1186/1687-9856-2014-10. Epub 2014 Jun 16.
288. American Academy of Pediatrics. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics* 2014;134:e620-38.
289. Stabler S. Vitamin B 12 Deficiency. *NEJM* Jan 2013, Vol 368:149-160
290. Guidelines and Protocols Advisory Committee, British Columbia Medical Association, Medical Services Commission (MSC). Cobalamin (vitamin B12) deficiency - investigation and management. MSC 2012 Jan PDF (Revised May 1, 2013)
291. Canadian Paediatric Society Position Statement: Vegetarian Diets in Children and Adolescents. *Paediatr Child Health* 2010; 15(5): 303-314 (Reaffirmed Feb 1, 2014)
292. Rasmussen et al. Vitamin B12 Deficiency in Children and Adolescents. *J Pediatr* 2001; 138 (1): 10-17
293. Firazyr (icatibant) [Health Canada Product Monograph]. Shire Orphan Therapies, LLC. Lexington, MA. Last revision: November 19, 2015.
294. Li JS et al. Dosing of Clopidogrel for Platelet Inhibition in Infants and young children primary results of the platelet inhibition in Children on Clopidogrel (PICOLO) *Circulation* 2008; 117:553-559
295. Litalien C, et al. Pharmacokinetics of proton pump inhibitors in children. *Clin Pharmacokinet* 2005; 44(5):441-466
296. Tolia V, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. *JPGN* 2002; 35:S308-312
297. Vandenplas Y et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). *J Pediatr Gastroenterol Nutr.* 2009 Oct;49(4):498-547.
298. Long S, Pickering LK, Prober CG. Principles and Practice of Pediatric Infectious Diseases. Long, Pickering and Prober, 4th ed. Saunders Elsevier, 2012.
299. Corbo MD and Lam J. Zinc Deficiency and its Management in the Pediatric Population: A Literature Review and Proposed Etiologic Classification. *J Am Acad Dermatol.* October 2013. 69(4): 616-624
300. ASPEN Position Paper: Recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. *Nutrition in Clinical Practice.* 2012; 27(4):440-491.
301. ESPGHAN. Iron, minerals, trace elements. *Journal of Pediatric Gastroenterology and Nutrition.* 2006; 41:S39-S46

302. Lowry CM, Marty FM, Vargas SO et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. *Transpl Infect Dis* 2007; 9: 121-125
303. Saiman L et al. Azithromycin in patients with cystic fibrosis chronically infected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 2003;290:1749-56.
304. Feldman WE, Moffitt S, and Sprow N, Clinical and Pharmacokinetic Evaluation of Parenteral Cefoxitin in Infants and Children, *Antimicrob Agents Chemother*, 1980, 17(4):669-74
305. Spino M, Chai RP, Isles AF et al. Cloxacillin absorption and disposition in cystic fibrosis. *J Pediatr* 1984;105(5):829-35
306. Young DC, Zobell JT, Waters CD et al. Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: IV. Colistimethate Sodium. *Pediatr Pulmonol* 2013; 48:1-7.
307. Rosenfeld et al. Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic Fibrosis. *JAMA* 2012; 307(21):2269-77.
308. Shneider BL, Magee JC, Bezerra JA, Haber B et al. Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia. *Pediatrics*. 2012; 130(3): e607-e614.
309. Lauer B and Spector N. Vitamins. *Pediatrics in Review*, Aug 2012; 33(8):339-352
310. Tangpricha V et al. An Update on the Screening, Diagnosis, Management, and Treatment of Vitamin D Deficiency in Individuals with Cystic Fibrosis: Evidence-Based Recommendations from the Cystic Fibrosis Foundation. *J Clin Endocrinol Metab* 2012;97(4):1-12.
311. Willot S et al. Effect of Ursodeoxycholic Acid on Liver Function in Children After Successful Surgery for Biliary Atresia. *Pediatrics* 2008;122:e1236-41.
312. El-Shabrawi MHF, et al. Medical Management of Chronic Liver Disease in Children (Part II): focus on the complications of CLD, and CLD that require special considerations. *Pediatr Drugs* 2011; 13(6): 371-83.
313. Eaton JE et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *Am J Gastroenterol* 2011; 106(9): 1638-45.
314. Hopps SA et al. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature. *J Oncol Pharm Pract* 2011; 22(3): 496-510.
315. Keeney GE et al. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. *Pediatrics* 2014; 133: 493-499.
316. Product Information: ORENCIA(R) intravenous subcutaneous injection, abatacept intravenous subcutaneous injection. Bristol-Myers Squibb (per manufacturer), Princeton, NJ, 2011.
317. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Care Res (Hoboken)* 2013; 65:1551.
318. Ruperto N et al. Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis. *Arthritis Rheum* 2010;62:1792-1802.

319. Ruperto N et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. *Lancet* 2008; 372: 383-91.
320. Turner et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. *JPGN* 2012;55: 340-361
321. Ruemmele et al. Consensus Guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. *J Crohn's and Colitis* 2014;8:1179-1207
322. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Care Res (Hoboken)* 2013; 65:1551.
323. Lovell DJ et al. Adalimumab with or without methotrexate for juvenile rheumatoid arthritis. *N Engl J Med* 2008;359:810-20
324. Kingsburey DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J et al. Safety, effectiveness and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. *Clin Rheumatol* 2014;33:1433-41.
325. Ilowite N et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. *Clin Rheumatol* 2009; 28:129-137.
326. Dewitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)* 2012;64:1001-10.
327. Wallace CA, Ringold S, Bohnsack J, Spalding SJ, Brunner HI et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. *J Rheumatol* 2014;41:2459-65
328. Horneff G. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. *Expert Opin Drug Safety* 2015;14:1111-26.
329. Kliegman RM, Stanton BF, St. Gernell JW, et al. eds. *Nelson Textbook of Pediatrics*. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.
330. Product Information: ACTEMRA tocilizumab solution for injection. Hoffmann-La Roche Limited. Mississauga, Ontario 2015.
331. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. *Ann Rheum Dis* 2015;74:1110-7.
332. Yokota S, Imagawa T, Mori M, Miyamae T, Takei S et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. *J Rheumatol* 2014;41:759-67.
333. Hawkins MJ, Dick AD, Lee RJW, Ramanan AV, Guly CM et al. Managing juvenile idiopathic arthritis-associated uveitis. *Survey of Ophthalmology* 2016;61:197-210.
334. Cormier, J, Chu, C. Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age. *Neuropsychiatric Disease and Treatment* 2013; 9: 295-306.
335. Vaisleib, I, Neft, R. Rapid Dosage Titration of Levetiracetam in Children. *Pharmacotherapy* 2008; 28 (3): 393-396
336. Brophy, G et al. Guidelines for the Evaluation and Management of Status Epilepticus. *Neurocritical Care* 2012; 17(1): 3-23

337. Guerrini, R., "Valproate as a Mainstay of Therapy for Pediatric Epilepsy," *Pediatr Drugs*. 2006; 8(2): 113-129
338. Graves NM and Kriel RL, "Rectal Administration of Antiepileptic Drugs in Children," *Pediatr Neurol*, 1987, 3(6):321-6
339. BCCH Pediatric Critical Care Program. Enteral and Parenteral nutrition support guidelines. Supplementation guidelines page 55. Last review date Apr 18, 2009.
340. Misra M et al. Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations. *Pediatrics* 2008, 122(2): 398-417
341. Friedman JN, Rieder MJ, Walton JM. Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age. *Paediatr Child Health*. 2014;19(9):485-98
342. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. *PEDIATRICS*. 2014 Nov 1;134(5):e1474-502.
343. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. In: The Cochrane Collaboration, editor. *Cochrane Database of Systematic Reviews* [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2013 [cited 2015 Mar 10]. Available from: <http://doi.wiley.com/10.1002/14651858.CD006458.pub3>
344. Chen Y-J, Lee W-L, Wang C-M, Chou H-H. Nebulized Hypertonic Saline Treatment Reduces Both Rate and Duration of Hospitalization for Acute Bronchiolitis in Infants: An Updated Meta-analysis. *Pediatr Neonatol*. 2014 Dec;55(6):431-8.
345. Maguire C, Cantrill H, Hind D, Bradburn M, Everard ML. Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis. *BMC Pulm Med*. 2015;15:148.
346. Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C. Nebulized Hypertonic Saline for Acute Bronchiolitis: A Systematic Review. *Pediatrics*. 2015 Oct;136(4):687-701.
347. Lumba-Brown A, Harley J, Lucio S et al. Hypertonic saline as a therapy for pediatric concussive pain. *Pediatr Emerg Care* 2014;30:139-45.
348. Mortazaci MM, Romeo AK, Deep A et al. Hypertonic saline for treating raised intracranial pressure: literature review and meta-analysis. *J Neurosurg* 012;116:210- 21.
349. Dupuis LL et al. Guideline for prevent of acute nausea and vomiting to antineoplastic medication in pediatric cancer patients. *Pediatric Oncology Group of Ontario*; Toronto, 2012
350. British Columbia Cancer Agency Policy Number III-20. Prevention and management of extravasation of chemotherapy. Revised Jan 2016.
351. Brier ME, Gaylor SK, McGovren JP, et al, "Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function," *J Clin Pharmacol*, 2011, 51(5):731-8.
352. Lipshultz SE, Scully RE, Lipsitz SR, et al, "Assessment of Dexrazoxane as a Cardioprotectant in Doxorubicin-Treated Children With High-Risk Acute Lymphoblastic Leukaemia: Long-Term Follow-Up of a Prospective, Randomised, Multicentre Trial," *Lancet Oncol*, 2010, 11(10):950-61
353. Daly K, Farrington E. Hypokalemia and hyperkalemia in infants and children: pathophysiology and treatment. *J Ped Health Care* 2013. 27(6): 486-96.

354. Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. *Arch Dis Child* 2012; 97: 376-380
355. Allen UD, Robinson JL; Canadian Paediatric Society Infectious Diseases and Immunization Committee. Prevention and management of neonatal herpes simplex virus infections. *Paediatr Child Health* 2014;19(4):201-6.
356. James SH, Whitley RJ. Treatment of Herpes simplex virus infections in pediatric patients: current status and future needs. *Clin Pharmacol Ther* 2010; 88(5):720-24
357. Feigin RD, Cherry J, Demmler-Harrison GJ, Kaplan SL. Textbook of pediatric infectious diseases. 7th ed. Philadelphia: Saunders Elsevier; 2014.
358. BCCH hematology/oncology bone marrow transplant supportive care guidelines 2012.
359. Bomgaars L et al. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. *Pediatr Blood Cancer* 2008; 51 (4): 504-8.
360. Kimberlin DW et al. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. *Clin Infect Dis* 2010; 50(2): 221
361. Reiss WB et al. Acetazolamide in the treatment of seizures. *Ann Pharmacother*, 1996; 30(5): 514-9.
362. Giraud C et al. In vitro Characterization of Clobazam metabolism by Recombinant Cytochrome P450 Enzymes: Importance of CP2C19. *Drug Metab Dispos* 2004; 32(11): 1279-86.
363. Malu C et al. Efficacy of sublingual lorazepam vs intrarectal diazepam for prolonged convulsions in sub-Saharan Africa. *J Child Neurol* 2014; 29(7): 895-902.
364. Friedman JN. Canadian Paediatric Society. Emergency management of the paediatric patient with generalized convulsive status epilepticus. *Paediatr Child Health* 2011; 16(2): 91-7.
365. Albani F et al. Immediate (overnight) switching from carbamazepine to oxycarbazepine monotherapy is equivalent to a progressive switch. *Seizure* 2004; 13: 254-263.
366. Yeung S, Ensom M. Phenytoin and enteral feedings: Does Evidence support an interaction? *Ann Pharmacother* 2000; 34: 896-904.
367. Dellinger RP et al. Surviving sepsis campaign: International guidelines for the management of severe sepsis and septic shock: 22008. *Intensive Care Med* 2008; 34: 17-60
368. Menon K et al. A systematic review and meta-analysis on the effect of steroids in pediatric shock. *Pediatr Crit Care Med* 2013; 14: 474-80.
369. Shulman D et al. Adrenal insufficiency: Still a cause of morbidity and death in childhood. *Pediatrics* 2007; 119: e484-94.
370. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2010;50:291-322.
371. Tahan S, Melli LCFL, Santos Mello C et al. Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum. *JPGN* 2013; 57:316-8.

372. Sato N et al. Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropin replacement therapy protocols. *Clin Pediatr Endocrinol* 2015; 24(2): 37-49.
373. Esposito C et al. Comparison of five different hormonal treatment protocols for children with cryptorchidism. *Scan J Urol Nephrol* 2003; 37: 247-9.
374. Bertelloni S et al. Hormonal treatment for unilateral inguinal testis: Comparison of four different treatments. *Horm Res* 2001; 55: 236-239.
375. BCCH Endocrine test protocols. April 19, 2016.
376. Mallick U et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. *N Engl J Med*. 2012 May 3;366(18):1674-85.
377. Francis GL et al. Management Guidelines for children with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2015; 25 (7): 716-759.
378. Hochadel, M. [Editor]. Mosby, *Drug Reference for Health Professions 5th Edition*.
379. Azad R et al. Role of intravenous fluorescein angiography in early detection and regression of retinopathy of prematurity. *J Pediatr Ophthalmol Strabismus*. 2008; 45 (1): 36-9.
380. Lepore D et al. Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity. *Ophthalmology*. 2011; 118 (1): 168-75
381. Fattel-Valevski A et al. Outbreak of life-threatening thiamine deficiency in infants in Israel caused by defective soy based formula. *Pediatr* 2005; 115 (2): e233-237.
382. Smithline HA et al. Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects *BMC Clinical Pharmacology*. 2012; 12 (4).
383. Charron T et al. Intravenous phosphate in the intensive care unit: More aggressive repletion regimens for moderate and severe hypophosphatemia. *Intensive Care Med* 2003; 29: 1273-8.
384. Mack Dr et al. methotrexate in patients with Crohn, *disease after 6-mercaptopurine. J Pediatr* 1998. 132: 830-5.
385. Expert Panel Recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology* 2014; 121: 785-796.
386. DeCamp LR, Byerley JS, Doshi N et al. Use of antiemetic agents in acute gastroenteritis: A systematic review and meta-analysis. *Pediatr Adolesc Med* 2008;162:858-65
387. Dupuis LL, Boodhan S, Holdsworth M et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. *Pediatr Blood Cancer* 2013;60:1073-82
388. Galardy PJ et al. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: A Children, *Oncology Group Report. BMJ* 2013; 163: 365-372.
389. Friedrichsdorf SJ et al. The management of pain in children with life-limiting illnesses. *Pediatr Clin N Am* 2007; 54: 645-72.
390. Hershey AD et al. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. *Headache* 2000; 40: 539-49.
391. Wasiewski WW. Preventative therapy in pediatric migraine. *J Child Neurol* 2001; 16: 71-8.

392. Bonfert M et al. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. *Neuropediatrics* 2013; 44: 3-19.
393. McGlone R et al. A comparison of intramuscular ketamine with high dose intramuscular midazolam with and without intranasal flumazenil in children before suturing. *Emerg Med J* 2001; 18: 34-8.
394. Health Canada Information Update. Health Canada, "Review recommends codeine only be used in patients aged 12 and over." June 6, 2013. Accessed at: <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/33915a-eng.php>
395. Health Canada Summary Safety Review. Codeine prescription products indicated for cough, "further assessing the risk of serious breathing problems in children and adolescents." December 9, 2015. Accessed at: <http://www.hc-sc.gc.ca/dhp-mpps/medeff/reviews-examens/codeine-eng.php>
396. Health Canada Information Update. New safety measures for prescription codeine and hydrocodone to further restrict use in children and adolescents. July 28, 2016. Accessed at <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59584a-eng.php>
397. FDA Drug Safety Communication. Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy. August 15, 2012. Accessed at: <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM339116.pdf>
398. Sheehy KA et al. Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. *BMC Pediatr* 2015; 15: 198
399. Pestieau SR et al. Prolonged perioperative infusion of low-dose ketamine does not alter opioid use after pediatric scoliosis surgery. *Pediatr Anesthesia* 2014; 24: 582-90.
400. Holh CM et al. Methotrimeprazine for the management of end-of-life symptoms in infants and children. *J Palliative Care* 2013; 29: 178-95.
401. Kleinman ME et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 2010; 122(suppl 3): S876-S908
402. Vanden Hoek TL et al. Part 12: cardiac arrest in special situations: 2010 American heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation* 2010; 122(suppl 3); S829-S861
403. Maxwell LG et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. *Anesth Anal* 2005; 100: 953-8.
404. Ganesh A et al. Pathophysiology and management of opioid-induced pruritus. *Drugs* 2007; 67(16): 2323-33.
405. Committee on Gynecologic Practice. The American College of Obstetrics and Gynecology. Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. *Obstetrics and Gynecology* 2014; 121: 891-6.
406. Kasap B. Sirolimus in pediatric renal transplantation. *Pediatr Transplantation* 2011; 15: 673-85.
407. Pape L et al. mTOR inhibitors in pediatric kidney transplantation. *Pediatr Nephrol* 2014; 29:1119-1129

408. Ganschow R et al. Growing experience with mTOR inhibitors in pediatric solid organ transplantation. *Pediatr Transplantation* 2013;17:694-706
409. Kang HJ et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomized, double-blind, phase 3 trial. *Lancet Oncol* 2015; 16: 385-94.
410. Grundberg S et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol – EASE. *J Clin Oncol* 2011; 29(11): 1495-1501.
411. Friedrichsdorf SJ and Nugent AP. Management of Neuropathic Pain in Children with Cancer. *Current Opinion in Supportive and Palliative Care*. 2013 Jun 7(2): 131-8
412. Lipidrescue.org
413. SOGC Clinical Practice Guidelines. Abnormal Uterine Bleeding in Pre-Menopausal Women. *J Obstet Gynaecol Can* 2013; 35(5): 473-475
414. SOGC Clinical Practice Guidelines. Canadian Contraception Consensus, Chapter 8: Progestin-only Contraception. *J Obstet Gynaecol Can* 2016; 38 (3): 279-300
415. Bhargava R, Chakravarti A. A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. *Am J Otolaryngology* 2014;35:766-70.
416. Baena-Cagnani CE, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. *Curr Med Res Opin* 2010;26:2047-55.
417. Gross S et al. Lacosamide in children with refractory status epilepticus. A multicenter Italian experience. *Eur J Pediatr Neurol* 2014; 18: 604-608
418. Gross S et al. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. *Eur J Pediatr Neurol* 2014; 18: 55-59
419. Miskin C et al. Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy. *J Child Neurol* 2016; 31(7): 925-929
420. Sant, Anna AM, et al. Use of cyproheptadine in young children with difficulties and poor growth in a pediatric feeding program. *J Pediatr Gastroenterol Nutr* 2014; 59: 674-678
421. Chavhan GB et al. MR enterography in children: Principles, technique, and clinical applications. *Indian J Radiol Imaging*. 2013 Apr-Jun; 23(2): 173 - 178.
422. Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. *Drugs*. 2007;67(9):1343-57
423. Tabbers MM et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. *J Pediatr Gastroenterol Nutr*. 2014;58(2):258-274.
424. El-Shabrawi MH et al. Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations. *Paediatr Drugs*. 2011; 13(6):371-83.
425. Blei AT et al. Hepatic Encephalopathy. *Am J Gastroenterol*. 2001; 96(7):1968-76
426. Li ST, Grossman DC, and Cummings P, "Loperamide Therapy for Acute Diarrhea in Children: Systematic Review and Meta-analysis," *PLoS Med*, 2007, 4(3):e98.
427. Kaplan MA et al. A multicenter randomized controlled trial of liquid loperamide product versus placebo in the treatment of acute diarrhea in children. *Clin Pediatr (Phila)* 1999; 38: 579-591.

428. Sandhu BK, Tripp JH, Milla PJ, et al, "Loperamide in Severe Protracted Diarrhoea," Arch Dis Child, 1983, 58(1):39-43
429. Rufo PA et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr. 2012;55(1):93-108
430. Health Canada. MedEffect Advisory. January 5, 2015. Metoclopramide ,Äi Abnormal involuntary movements (Extrapyramidal symptoms) in children. <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43167a-eng.php>
431. Koseoglu V, Kurekci AE, Sorici U. Comparison of the efficacy and side effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: A prospective randomized study. Eur J Pediatr 1998;157:806-10.
432. Vanderplas Y et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009;49:498-547.
433. Blackmer AB et al. Constipation in the Pediatric Patient: An Overview and Pharmacologic Considerations. J Pediatr Health Care. 2010; 24: 385-399.
434. Tammara BK et al, "Randomized, Open-Label, Multicentre Pharmacokinetic Studies of Two Dose Levels of Pantoprazole Granules in Infants and Children Aged 1 Month Through <6 Years With Gastro-oesophageal Reflux Disease," Clin Pharmacokinet, 2011, 50(8):541-50.
435. Ward RM et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with GERD. J Clin Pharmacol. 2011;51(6):876-887.
436. Pettersen G et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. Br J Clin Pharmacol. 2009;67(2):216-227
437. Tuggle DW et al. The safety and cost-effectiveness of polyethylene glycol electrolyte solution bowel preparation in infants and children. J Pediatr Surg 1987; 22(6): 513-5.
438. Sondheimer JM et al. Safety, efficacy and tolerance of intestinal lavage in pediatric patients undergoing diagnostic colonoscopy. J Pediatr 1991; 119(1):148-52
439. Turner et al. Pico-Salax versus polyethylene glycol for bowel cleanout before colonoscopy in children: a randomized controlled trial. Endoscopy. 2009;41(12):1038-45.
440. Carroll MW and Jacobson K. Gastroesophageal reflux disease in children and adolescents. Pediatr Drugs 2012; 14(2):79-89.
441. ASHP Therapeutic guidelines on stress ulcer prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56(4):347-379
442. Yildizdas D et al. Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. J Crit Care. 2002 Dec;17(4):240-5.
443. Lopriore E et al. Ventilator-associated pneumonia and upper airway colonisation with Gram negative bacilli: the role of stress ulcer prophylaxis in children. Intensive Care Med. 2002 Jun;28(6):763-7

444. Hall B, Chesters J, Robinson, A. Infantile colic: A systematic review of medical and conventional therapies. *J Paediatrics Child Health* 2012; 48: 128-137.
445. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson Disease: An update. *Hepatology* 2008;47:2089-111
446. Quaas AM et al. Prevention and treatment of uterine bleeding in hematologic malignancy. *European Journal of Obstetrics and Gynecology and Reproductive Biology* 2007; 134: 3-8
447. Martin-Johnston MK et al. Therapeutic amenorrhea in patients at risk for thrombocytopenia. *Obstetrical and gynecological Survey* 2008: 63(6): 395-402.
448. James, AH et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. *Eur J Obstet Gynecol Reprod Biol* 2011; 158(2): 124-34.
449. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol* 2017: 35 3240-3261.
450. Buchen S et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. *Br J Cancer* 2005; 92: 480-487.
451. Bradley AM et al. Successful use of intrathecal carboxypeptidase G2 for intrathecal methotrexate overdose: A clinical case study and review of the literature. *Clin Lymphoma* 2013; 13(2):166-70.
452. Voraxaze product monograph
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/1253271bl.pdf
453. Tengborn L et al. Tranexamic acid, An old drug still going strong and making a revival. *Thrombosis research* 2015; 135: 231-242.
454. Khemani RG, Randolph A, Markovitz B. Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults. *Cochrane Database Syst Rev* 2009;3:CD001000.
455. Sharar SR, Bratton SL, Carrougher GJ et al. Comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. *J Burn Care Rehabil* 1998;19:516-21.
456. Sharar SR, Carrougher GJ, Selzer K et al. Comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. *J Burn Care Rehabil* 2002;23:27-31
457. Mahar PJ, Rana JA, Kennedy CS et al. Randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries. *Pediatr Emerg Care* 2007;23:544-8
458. Wheeler M, Birmingham PK, Dsida RM et al. Uptake pharmacokinetics of the Fentanyl Oralet in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. *Pediatric Anaesthesia* 2002;12:594-9.
459. Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. *Palliative Medicine* 2001;15:323-8.
460. Escudero C et al. The medical management of arrhythmias. *Current Treatment Options in Cardiovascular Medicine*. 2012 Oct; 14(5): 455-72.
461. Escudero C et al. Overview of antiarrhythmic drug therapy for supraventricular tachycardia in children. *Progress in Pediatric Cardiology* 2013; 35 (1): 55-63.

462. Patel NH et al. Evaluation and management of pediatric hypertensive crises: hypertensive urgency and hypertensive emergencies. *Open Access Emerg Med* 2012; 4: 85-92.
463. Delgado MR et al. Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). *Neurology* 2010; 74: 336-343.
464. Klein EJ, Brown JC, Kobayashi A et al. A randomized clinical trial comparing oral, aerosolized intranasal, and aerosolized buccal midazolam. *Ann Emerg Med* 2011;58:323-9.
465. Jazz Pharmaceuticals Ireland Limited. Defitelio, Ñ Product Monograph. 10 July 2017.
466. Defibrotide. Lexi-comp Online. Updated 5/1/2017. Accessed December 2017
467. Richardson PG et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive/sinusoidal obstruction syndrome improves day +100 survival following haematopoietic stem cell transplantation. *Br J Haematol* 2017. 178(1): 112-118.
468. Zulanga M. Chylothorax after surgery for congenital heart disease. *Current Opinion in Pediatrics* 2012. 24(3): 291-4.
469. Demirkilek H, Shah P, Bhushan Arya V et al. Long-term follow-up of children with congenital hyperinsulinism on octreotide therapy. *J Clin Endocrinol Metab* 2014;99:3660-7.
470. Eroglu Y, Emerick KM, Whitingon PF et al. Octreotide therapy for control of acute gastrointestinal bleeding in children. *J Pediatr Gastroenterol Nutr* 2004;38:41-7
471. Wise-Faberowski L et al. Perioperative management of diabetes insipidus in children. *J Neurosurg Anesthesiol* 2004; 16:220-3
472. Horimoto Y, Tomie H, Hanzawa K et al. Scopolamine patch reduces postoperative emesis in paediatric patients following strabismus surgery. *Can J Anesthesia* 1991;38:441-4
473. Lewis DW, Fontana C, Mehallick LK et al. Transdermal scopolamine for reduction of drooling in developmentally delayed children. *Developmental medicine and child neurology* 1994;36:484-6
474. Zelenitsky S, Ariano R, Harding G, Forrest A. Evaluating ciprofloxacin dosing for *Pseudomonas aeruginosa* infection by using clinical outcome-based Monte Carlo simulations. *Antimicrob Agents Chemother* 2005;10:4009-14.
475. Crash-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant hemorrhage (CRASH-2): a randomized placebo-controlled trial. *Lancet* 2010;376:23-32
476. Eckert MJ, Wetin TM, Tyner SD et al. Tranexamic acid administration to pediatric trauma patients in the combat setting: The pediatric trauma and tranexamic acid study (PED-TRAX) *J Trauma Acute Care Surg* 2014;77:852-8.
477. Faraoni D, Goobie SM. The efficacy of antifibrinolytic drugs in children undergoing noncardiac surgery: A systematic review of the literature. *Anesth Analg* 2014;118:628-36
478. Skeens M et al. Twice daily I.V. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. *Bone Marrow Transplant* 2012. 47(11): 1415-8.

479. Ammar A, Mahmoud K, Kasemy Z. A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. *Acta Anaesthesiologica Scandinavica*. 2017;61(4):374-380.
480. Won YJ, Lim BG, Lee DK, Kim H, Kong H, Lee IO. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients: A systematic review and meta-analysis. *Medicine*. 2016;95(34)
481. Godwin SA, Burton JH, Gerardo CJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. *Ann Emerg Med*. 2014;63(2):247-258. [PubMed 24438649]
482. Chidambaran V et al. Propofol: a review of its role in pediatric anesthesia and sedation. *CNS Drugs* 2015; 29(7): 543-563.
483. Fujita M, Sato K, Nishioka H, Sakai F. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. *Cephalalgia*. 2014 Apr;34(5):365-75
484. Firazyr (icatibant) [Health Canada Product Monograph]. Shire Orphan Therapies, LLC. Lexington, MA. Last revision: November 19, 2015.
485. Farkas H et al. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. *J Allergy Clin Immunol Pract*. 2017 Nov - Dec;5(6):1671-1678.e2
486. Flank J et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: A retrospective multi-center review. *Pediatr Blood Cancer* 2015; 72: 496-501.